Kallikrein Inhibitor - Pipeline Insight, 2022
This report can be delivered to the clients within 2-3 working days
DelveInsight’s, “Kallikrein Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Kallikrein Inhibitor - Pipeline Insights, 2021: Overview
Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma prekallikrein is activated to plasma kallikrein by activated factor XII or prolylcarboxypeptidase. Plasma kallikrein regulates the activity of multiple proteolytic cascades in the cardiovascular system such as the intrinsic pathway of coagulation, the kallikrein-kinin system, the fibrinolytic system, the renin-angiotensin system, and the complement pathways. As such, plasma kallikrein plays a central role in the pathogenesis of thrombosis, inflammation, and blood pressure regulation. Under physiological conditions, plasma kallikrein serves as a cardioprotective enzyme. However, its increased plasma concentration or hyperactivity perpetuates cardiovascular disease (CVD).
'Kallikrein Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Kallikrein Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Kallikrein Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kallikrein Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Kallikrein Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs
Further product details are provided in the report……..
Kallikrein Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment
This segment of the report provides insights about the different Kallikrein Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
Kallikrein Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kallikrein Inhibitor - Pipeline Insights, 2021 drugs.
Kallikrein Inhibitor - Pipeline Insights, 2021 Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Kallikrein Inhibitor - Pipeline Insight, 2022” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Kallikrein Inhibitor - Pipeline Insights, 2021: Overview
Plasma prekallikrein is the liver-derived precursor of the trypsin-like serine protease plasma kallikrein, and circulates in plasma bound to high molecular weight kininogen. Plasma prekallikrein is activated to plasma kallikrein by activated factor XII or prolylcarboxypeptidase. Plasma kallikrein regulates the activity of multiple proteolytic cascades in the cardiovascular system such as the intrinsic pathway of coagulation, the kallikrein-kinin system, the fibrinolytic system, the renin-angiotensin system, and the complement pathways. As such, plasma kallikrein plays a central role in the pathogenesis of thrombosis, inflammation, and blood pressure regulation. Under physiological conditions, plasma kallikrein serves as a cardioprotective enzyme. However, its increased plasma concentration or hyperactivity perpetuates cardiovascular disease (CVD).
'Kallikrein Inhibitor - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kallikrein Inhibitor - Pipeline Insights, 2021 pipeline landscape is provided which includes the disease overview and Kallikrein Inhibitor - Pipeline Insights, 2021 treatment guidelines. The assessment part of the report embraces, in depth Kallikrein Inhibitor - Pipeline Insights, 2021 commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kallikrein Inhibitor - Pipeline Insights, 2021 collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Kallikrein Inhibitor - Pipeline Insights, 2021 R&D. The therapies under development are focused on novel approaches to treat/improve Kallikrein Inhibitor - Pipeline Insights, 2021.
This segment of the Kallikrein Inhibitor - Pipeline Insights, 2021 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kallikrein Inhibitor - Pipeline Insights, 2021 Emerging Drugs
- THR-149: Oxurion
- Donidalorsen: Ionis Pharmaceuticals
Further product details are provided in the report……..
Kallikrein Inhibitor - Pipeline Insights, 2021: Therapeutic Assessment
This segment of the report provides insights about the different Kallikrein Inhibitor - Pipeline Insights, 2021 drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Kallikrein Inhibitor - Pipeline Insights, 2021
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Kallikrein Inhibitor - Pipeline Insights, 2021: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kallikrein Inhibitor - Pipeline Insights, 2021 drugs.
Kallikrein Inhibitor - Pipeline Insights, 2021 Report Insights
- Kallikrein Inhibitor - Pipeline Insights, 2021 Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Kallikrein Inhibitor - Pipeline Insights, 2021 drugs?
- How many Kallikrein Inhibitor - Pipeline Insights, 2021 drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kallikrein Inhibitor - Pipeline Insights, 2021?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kallikrein Inhibitor - Pipeline Insights, 2021 therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Kallikrein Inhibitor - Pipeline Insights, 2021 and their status?
- What are the key designations that have been granted to the emerging drugs?
- Oxurion
- Intellia Therapeutics
- Ionis Pharmaceuticals
- KalVista Pharmaceuticals
- Astria Therapeutics
- THR-149
- NTLA2002
- KVD-824
- Donidalorsen
- JNJ-78278343
- STAR-0215
Introduction
Executive Summary
Kallikrein Inhibitor - Pipeline Insights, 2021: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
THR-149: Oxurion
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
JNJ-78278343: Janssen Research & Development
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
STAR-0215: Astria Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Kallikrein Inhibitor - Pipeline Insights, 2021 Key Companies
Kallikrein Inhibitor - Pipeline Insights, 2021 Key Products
Kallikrein Inhibitor - Pipeline Insights, 2021- Unmet Needs
Kallikrein Inhibitor - Pipeline Insights, 2021- Market Drivers and Barriers
Appendix
Executive Summary
Kallikrein Inhibitor - Pipeline Insights, 2021: Overview
• Causes
• Mechanism of Action
• Signs and Symptoms
• Diagnosis
• Disease Management
Pipeline Therapeutics
• Comparative Analysis
Therapeutic Assessment
• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
• Comparative Analysis
Drug Name: Company Name
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
• Comparative Analysis
THR-149: Oxurion
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Early stage products (Phase I)
• Comparative Analysis
JNJ-78278343: Janssen Research & Development
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
• Comparative Analysis
STAR-0215: Astria Therapeutics
• Product Description
• Research and Development
• Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
• Comparative Analysis
Kallikrein Inhibitor - Pipeline Insights, 2021 Key Companies
Kallikrein Inhibitor - Pipeline Insights, 2021 Key Products
Kallikrein Inhibitor - Pipeline Insights, 2021- Unmet Needs
Kallikrein Inhibitor - Pipeline Insights, 2021- Market Drivers and Barriers
Appendix
LIST OF TABLES
Table 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Kallikrein Inhibitor - Pipeline Insights, 2021
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
